Form 8-K Filing by Medline Inc.

This Form 8-K filing by Medline Inc. reports on several material events occurring on December 16, 2025, primarily related to its initial public offering (IPO). The company entered into various definitive agreements, including a Second Amended and Restated Limited Partnership Agreement of Medline Holdings, LP, a Tax Receivable Agreement, an Exchange Agreement, and a Registration Rights Agreement. Additionally, several Director Nomination Agreements were established with entities affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC, the Mills Family, and Hux Investment Pte. Ltd. The filing also announces the appointment of Todd M. Bluedorn to the Board of Directors and his position on the Audit Committee, along with the adoption of the Medline Inc. 2025 Omnibus Incentive Plan and the 2025 Employee Stock Purchase Plan. Amendments to the company's Amended and Restated Certificate of Incorporation and Bylaws became effective, detailing the authorized capital stock. On December 18, 2025, Medline Inc. completed its IPO, issuing 248,439,654 shares of Class A common stock at $29.00 per share. Proceeds were used to purchase units in Medline Holdings, LP, repay debt, and cover offering expenses.